Squarepoint
AVTX icon

Squarepoint’s Avalo Therapeutics AVTX Stock Holding History

Squarepoint’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.9M Buy
589,245
+507,960
+625% +$8.03M 0.01% 1057
2026
Q1 		$1.21M Buy
81,285
+40,431
+99% +$632K ﹤0.01% 2610
2025
Q4 		$742K Buy
+40,854
New +$690K ﹤0.01% 2867
2021
Q4 		– Sell
-6
Closed -$41K – 3151
2021
Q3 		$41K Buy
+6
New +$48.6K ﹤0.01% 2789
2021
Q2 		– Sell
-9
Closed – – 3215
2021
Q1 		$0 Hold
9
– – ﹤0.01% 3099
2020
Q4 		$0 Hold
9
– – ﹤0.01% 2910
2020
Q3 		$58K Sell
9
-3
-25% -$22.5K ﹤0.01% 2353
2020
Q2 		$92K Sell
12
-5
-29% -$36.3K ﹤0.01% 2031
2020
Q1 		$119K Buy
+17
New +$180K ﹤0.01% 1605

Other funds holding AVTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Squarepoint's AVTX Position: Q2 2026 in Review

Squarepoint increased its Avalo Therapeutics (AVTX) stake by 625% in Q2 2026, buying an estimated $8.03M and bringing the position to 589,245 shares worth $10.9M. The position accounts for 0.01% of the portfolio, ranked #1057.

Squarepoint first reported a position in AVTX in Q1 2020 and has held it in 9 quarters since. 126 funds tracked by Wall St. Rank hold AVTX as of Q2 2026.

  • Squarepoint held 589,245 shares of Avalo Therapeutics worth $10.9M as of Q2 2026.
  • Squarepoint bought 507,960 Avalo Therapeutics shares in Q2 2026, an estimated $8.03M.
  • Avalo Therapeutics made up 0.01% of Squarepoint's portfolio in Q2 2026, its #1057 holding.
  • Squarepoint first reported a position in Avalo Therapeutics in Q1 2020 and has held it in 9 quarters since.
  • 126 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.